SLC2A9 and chronic kidney disease: Dotinurad, a novel uricosuric agent that specifically inhibits renal URAT1 but not GLUT9 [30], has also been shown to be effective in slowing the decline of eGFR in a retrospective study involving patients with CKD [31].